Acinetobacter baumannii at a tertiary-care teaching hospital in Jerusalem, Israel

J Clin Microbiol. 2001 Jan;39(1):389-91. doi: 10.1128/JCM.39.1.389-391.2001.

Abstract

In a retrospective 10-year analysis of 3,536 patient-unique isolates, Acinetobacter baumannii imipenem susceptibility declined from 98.1 (1990) to 64.1% (2000), and ciprofloxacin susceptibility decreased from 50.5 to 13.1%. Imipenem median zone diameters decreased from 27. 7 (1997) to 18.8 mm (2000). No outbreaks were detected. Two clusters were identified for 41 strains genotyped by pulsed-field gel electrophoresis, but imipenem resistance was not clonal.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter / drug effects*
  • Acinetobacter / genetics
  • Acinetobacter Infections / epidemiology
  • Acinetobacter Infections / microbiology*
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Infective Agents / pharmacology
  • Ciprofloxacin / pharmacology
  • Drug Resistance, Microbial / genetics
  • Electrophoresis, Gel, Pulsed-Field
  • Hospitals, Teaching
  • Humans
  • Imipenem / pharmacology*
  • Israel / epidemiology
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Thienamycins / pharmacology

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Thienamycins
  • Ciprofloxacin
  • Imipenem